

# Roberto Moretto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1656387/publications.pdf>

Version: 2024-02-01

66  
papers

1,297  
citations

471371

17  
h-index

377752

34  
g-index

66  
all docs

66  
docs citations

66  
times ranked

1892  
citing authors

#	ARTICLE	IF	CITATIONS
1	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	5.1	196
2	First-line chemotherapy for mCRC—a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 607-619.	12.5	138
3	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017, 22, 601-608.	1.9	108
4	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	1.9	94
5	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020, 123, 403-409.	2.9	93
6	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 876-887.	5.1	83
7	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 30-36.	2.9	56
8	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	1.1	53
9	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the “BRAF BeCool” study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
10	First-line therapy for mCRC—the influence of primary tumour location on the therapeutic algorithm. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 113-113.	12.5	35
11	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 315-321.	0.3	28
12	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	3.0	27
13	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 7859-7866.	0.8	25
14	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	3.2	24
15	Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom?. <i>Clinical Colorectal Cancer</i> , 2014, 13, 185-191.	1.0	23
16	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	2.0	20
17	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6.	1.0	20
18	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma. <i>Anti-Cancer Drugs</i> , 2013, 24, 980-985.	0.7	19

#	ARTICLE	IF	CITATIONS
19	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020, 139, 81-89.	1.3	17
20	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1283-1292.	1.1	12
21	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 314-317.	1.0	12
22	Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 2818-2829.	3.2	12
23	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 685-698.	1.2	11
24	Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials. <i>Cancers</i> , 2022, 14, 52.	1.7	11
25	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017, 2, e000241.	2.0	10
26	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	1.3	10
27	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492094669.	0.6	9
28	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	2.9	9
29	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. <i>Cancer Treatment Reviews</i> , 2022, 106, 102382.	3.4	9
30	Primary hepatic lymphoma in a patient with previous rectal adenocarcinoma: a case report and discussion of etiopathogenesis and diagnostic tools. <i>International Journal of Hematology</i> , 2012, 95, 320-323.	0.7	8
31	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	1.0	7
32	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021, 124, 183-190.	2.9	7
33	A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3557-3557.	0.8	7
34	Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 165, 116-124.	1.3	6
35	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	2.9	6
36	Tumor-to-tumor metastasis. <i>Anti-Cancer Drugs</i> , 2013, 24, 759-764.	0.7	5

#	ARTICLE	IF	CITATIONS
37	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	1.3	5
38	Basaloid Squamous Cell Carcinoma: A Rare Tumor at the Esophagogastric Junction and an Unexpected Durable Complete Response to FOLFOX-4. <i>Oncology Research and Treatment</i> , 2014, 37, 55-58.	0.8	3
39	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. <i>Colorectal Cancer</i> , 2018, 7, CRC01.	0.8	3
40	Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. <i>Investigational New Drugs</i> , 2020, 38, 92-98.	1.2	3
41	Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer. <i>International Journal of Cancer</i> , 2020, 146, 2652-2654.	2.3	3
42	Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3542-3542.	0.8	3
43	Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 675-675.	0.8	3
44	Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation. , 2018, , .		3
45	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
46	Genetic variants of <i>hENT-1</i> to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3580-3580.	0.8	2
47	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the "BRAF, BeCool" platform.. <i>Journal of Clinical Oncology</i> , 2018, 36, 639-639.	0.8	2
48	BRAF mutant metastatic colorectal cancers: new arrows in our quiver. <i>Annals of Translational Medicine</i> , 2019, 7, S367-S367.	0.7	1
49	Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3540-3540.	0.8	1
50	Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11508-11508.	0.8	1
51	Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference.. <i>Journal of Clinical Oncology</i> , 2017, 35, 615-615.	0.8	1
52	A still missing piece of the FIRE-3 puzzle. <i>Lancet Oncology</i> , The, 2016, 17, e515.	5.1	0
53	Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. <i>Annals of Oncology</i> , 2017, 28, iii94-iii95.	0.6	0
54	<i>BRAF</i> V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases. <i>JAMA Surgery</i> , 2018, 153, 1162.	2.2	0

#	ARTICLE	IF	CITATIONS
55	Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 1749-1759.	1.1	0
56	Angiopoietin-2 early increase to predict benefit from regorafenib in metastatic colorectal cancer (mCRC) patients: The prospective REGOLAND study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15566-e15566.	0.8	0
57	Bevacizumab maintenance in metastatic colorectal cancer: How long?. <i>World Journal of Clinical Cases</i> , 2014, 2, 717.	0.3	0
58	Risk factors for cancer-related venous thromboembolism in ambulatory patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20625-e20625.	0.8	0
59	Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15054-e15054.	0.8	0
60	Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3627-TPS3627.	0.8	0
61	Abstract LB-238: Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC). , 2017, , .		0
62	Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver limited metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e15511-e15511.	0.8	0
63	The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15593-e15593.	0.8	0
64	Abstract 1823: Identification of molecular determinants of vinorelbine resistance in BRAF(V600E) mutated chemorefractory metastatic colorectal cancer patients. , 2018, , .		0
65	Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3534-3534.	0.8	0
66	Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3540-3540.	0.8	0